Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.67 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.67 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459394 | 0.87 | OPRM1 (0.57) | HSD17B10OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL22605436 | 0.85 | HSD17B10 (0.68) | HSD17B10OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL12490707 | 0.85 | HSD17B10 (0.68) | HSD17B10OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL6402803 | 0.84 | OPRM1 (0.74) | OPRM1OPRL1OPRD1OPRK1SLC6A9 | |
| SCHEMBL9912156 | 0.84 | OPRL1 (0.74) | HSD17B10OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL5962569 | 0.84 | SLC6A9 (0.73) | HSD17B10OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL5962890 | 0.84 | OPRM1 (0.79) | HSD17B10OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL21688403 | 0.84 | HSD17B10 (0.63) | HSD17B10OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL5781495 | 0.84 | HSD17B10 (0.67) | HSD17B10OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL21634299 | 0.83 | HSD17B10 (0.62) | HSD17B10OPRM1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023118319-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2023-06-29 | — | — | WO | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-11084847-B2 | Polyamide compound and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-20200163336-A1 | CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2020-05-28 | — | — | US | disclosed |
| WO-2020056249-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20070010531-A1 | Substituted pyrazole compounds | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010531-A1 | Substituted pyrazole compounds | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| WO-2005060981-A2 | PHARMACEUTICAL COMPOSITIONS | SCHERING CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20040138235-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | SCHERING CORPORATION | 2004-07-15 | — | — | US | disclosed |
| WO-2003032996-A1 | IMIDAZO (4,3-E)-1,2,4-TRIAZOLO(1,5-C) PYRIMIDINES AS ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084847-B2 | Polyamide compound and use thereof | OPRK1, OPRM1, OPRD1 | HSD17B10 2296/4885OPRM1 2/4885OPRL1 4/4885 |
| US-20070010531-A1 | Substituted pyrazole compounds | HTR3A, HTR1A, HTR1D | HSD17B10 3097/4885OPRM1 28/4885OPRL1 31/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | HSD17B10 2944/4885OPRM1 5/4885OPRL1 2/4885 |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SSTR2, SSTR5, SSTR3 | HSD17B10 1463/4885OPRM1 98/4885OPRL1 65/4885 |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | HSD17B10 883/4885OPRM1 3/4885OPRL1 2/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | HSD17B10 1091/4885OPRM1 814/4885OPRL1 815/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | HSD17B10 3340/4885OPRM1 724/4885OPRL1 88/4885 |
| US-20200163336-A1 | CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | H1-10, TAAR1, C5 | HSD17B10 1754/4885OPRM1 2078/4885OPRL1 2634/4885 |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | HSD17B10 2944/4885OPRM1 5/4885OPRL1 2/4885 |
| US-20040138235-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | ADORA2A, ADORA3, ADORA2B | HSD17B10 4596/4885OPRM1 249/4885OPRL1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.